Company: BLLN
Filing Date: 2025-08-11
Form Type: DRS/A
Source: 0000950123-25-007483
Chunk: 264

Company: BillionToOne, Inc.
Filing Date: 2025-08-11
Form: DRS/A
Chunk 264
---
. Tsao sold an aggregate of 196,126 shares of common stock for aggregate cash proceeds of $4,999,977.43 at a price per share of $25.4937.

In April 2022, Dr. Atay entered into stock purchase agreements with us and certain affiliates of Libertus Capital. Pursuant to these agreements, Dr. Atay sold
an aggregate of 196,126 shares of our common stock for $4,999,977.41 aggregate cash proceeds at a price of $25.4937 per share.

In November 2022, entities affiliated
with Libertus Capital, which holds more than 5% of our capital stock, purchased an aggregate of 87,700 shares of our common stock for $1,788,641.00 aggregate cash proceeds at a price of $20.395 per share, which included 30,000 shares purchased from
Shan Riku Sakakibara, our Chief Product Officer.

In June 2024, entities affiliated with Libertus Capital, which holds more than 5% of our capital stock, purchased
an aggregate of 52,750 shares of our common stock for $1,182,655.00 aggregate cash proceeds at a price of $22.42 per share, which included 9,500 shares purchased from John ten Bosch, our Senior Vice President of Laboratory Operations.

Directed share program

At our request, the underwriters have reserved up to
approximately shares of Class A common stock being offered by this prospectus for sale, at the initial public offering price, to our officers, directors and employees through a directed share program. The directed share program will
not limit the ability of our directors, officers or holders of more than 5% of our capital stock, to purchase more than $120,000 in value of our Class A common stock. We do not currently know the extent to which these related persons will
participate in our directed share program, if at all, or the extent to which they will purchase more than $120,000 in value of our Class A common stock.

Investors’ rights agreement

We have entered into an Amended and
Restated Investors’ Rights Agreement, dated May 14, 2024, by and among the Company and the investors listed on schedule A thereto (the IRA), including entities with which certain of our directors are affiliated. These stockholders are
entitled to rights with respect to the registration of their shares following this offering. For a